ALT
Altimmune, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.25
+0.31%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.23
From 52W high−47.41%
Volume12.18M
Market cap$632.18M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.23
From 52W high
−47.41%
Volume
12.18M
Market cap
$632.18M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
P/E (TTM)
—
RSI (14)
51.6
MomentumView details →
1D Return
+0.31%
YTD Return
−11.22%
SummaryUpdated Jun 1, 2026
Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Gaithersburg, Maryland. Originally known as Vaxin Inc., the company changed its name to Altimmune in September 2015. The company went public in May 2017 and focuses on developing innovative treatments for metabolic diseases, particularly obesity and liver conditions. Altimmune has evolved from its early vaccine development roots to become a specialized developer of dual-mechanism therapies targeting the growing global obesity and non-alcoholic fatty liver disease epidemics.
Similar companies
Latest newsMore news →
Dimensional Fund Advisors LP increased its stake in Altimmune, Inc. by 268.7% during the first quarter, acquiring an additional 762,223 shares, as disclosed in a Form 13F filing with the SEC.38d agoAltimmune, Inc. held its Q2 2026 earnings call on August 12, 2026, to discuss financial results and business updates.39d ago